Clinical Research Directory
Browse clinical research sites, groups, and studies.
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Sponsor: Changhai Hospital
Summary
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages. The population undergoing low-dose computed tomography (LDCT) screening significantly overlaps with those at high risk for PDAC; however, traditional imaging methods have limited sensitivity for detecting pancreatic lesions. This study utilizes the Pancreatic Cancer Detection with Artificial Intelligence (PANDA) system to enhance LDCT for pancreatic cancer screening in a prospective, multicenter, observational cohort. PANDA will analyze LDCT images, followed by a multidisciplinary team (MDT) reassessment of abnormal interpretations. Based on MDT evaluation, individuals will be recalled for further examination, placed under a personalized follow-up plan, or monitored for at least one year. The primary outcomes include pancreatic cancer detection rate, positive predictive value, consensus rate, and recall rate, while secondary outcomes focus on early-stage cancers, resectable tumors, and safety indicators such as false positive rates and unnecessary procedures. This study aims to assess the effectiveness and safety of AI-assisted LDCT for PDAC detection, providing a practical solution for improving public health and enhancing early diagnostic capabilities.
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400000
Start Date
2025-08-15
Completion Date
2032-12-30
Last Updated
2025-08-12
Healthy Volunteers
Yes
Conditions
Interventions
Diagnostic Evaluation for Positive AI Findings
MDT will review positive AI findings (including PDAC, pancreatic precursor lesions and benign lesion) cases to determine next steps: (1) Suspected PDAC and pancreatic precursor lesions are referred for hospital examination with diagnostic results collected; (2) Benign lesion cases receive personalized monitoring until endpoint events or study end; (3) Cases with positive AI findings but MDT-confirmed normal pancreatic issues receive at least one year of follow-up. If any abnormal results arise, management will transition to either plan (1) or (2).
Locations (5)
Meinian Onehealth Healthcare Holdings Co., Ltd
Shanghai, Shanghai Municipality, China
Ruici Medical Examination Institution
Shanghai, Shanghai Municipality, China
Changhai Hospital
Shanghai, Shanghai Municipality, China
Jiaxing University Affiliated Second Hospital
Jiaxing, Zhejiang, China
Ningbo University Affiliated People's Hospital
Ningbo, Zhejiang, China